Alpha Mark Advisors, LLC Clovis Oncology, Inc. Transaction History

Alpha Mark Advisors, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Aug 02, 2019	SELL	$12.81 - $25.67 $2,497 - $5,005	-195 Closed	0 $0
Q2 2018 Aug 03, 2018	BUY	$42.06 - $62.4 $8,201 - $12,168	195 New	195 $9,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Mark Advisors, LLC with notifications on news.